PTJ
OCUL icon

Paul Tudor Jones’s Ocular Therapeutix OCUL Stock Holding History

Paul Tudor Jones’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.13M Sell
522,663
-91,715
-15% -$831K 0.01% 1262
2026
Q1 		$5.2M Buy
614,378
+119,586
+24% +$1.14M 0.01% 1138
2025
Q4 		$6.01M Buy
494,792
+332,893
+206% +$4.04M 0.01% 1041
2025
Q3 		$1.89M Buy
+161,899
New +$1.94M ﹤0.01% 1842
2025
Q2 		– Sell
-79,648
Closed -$584K – 3613
2025
Q1 		$584K Buy
+79,648
New +$612K ﹤0.01% 2185
2024
Q2 		– Sell
-74,531
Closed -$678K – 2653
2024
Q1 		$678K Sell
74,531
-64,200
-46% -$456K ﹤0.01% 1517
2023
Q4 		$619K Sell
138,731
-35,436
-20% -$105K 0.01% 1679
2023
Q3 		$547K Sell
174,167
-26,676
-13% -$109K 0.01% 1632
2023
Q2 		$1.04M Buy
200,843
+132,459
+194% +$788K 0.01% 1299
2023
Q1 		$360K Sell
68,384
-30,954
-31% -$147K 0.01% 1809
2022
Q4 		$279K Buy
99,338
+37,563
+61% +$124K 0.01% 1950
2022
Q3 		$256K Buy
61,775
+10,736
+21% +$54.1K 0.01% 1895
2022
Q2 		$205K Buy
+51,039
New +$193K 0.01% 1809
2022
Q1 		– Sell
-40,987
Closed -$286K – 2477
2021
Q4 		$286K Sell
40,987
-53,725
-57% -$417K ﹤0.01% 1881
2021
Q3 		$947K Buy
+94,712
New +$1.06M 0.02% 1195
2016
Q1 		– Sell
-12,700
Closed -$119K – 1905
2015
Q4 		$119K Buy
+12,700
New +$137K ﹤0.01% 1513
2015
Q3 		– Sell
-17,663
Closed -$371K – 1687
2015
Q2 		$371K Buy
+17,663
New +$438K 0.01% 974

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's OCUL Position: Q2 2026 in Review

Paul Tudor Jones reduced its Ocular Therapeutix (OCUL) stake by 15% in Q2 2026, selling an estimated $831K and leaving 522,663 shares worth $5.13M. The position accounts for 0.01% of the portfolio, ranked #1262.

Paul Tudor Jones first reported a position in OCUL in Q2 2015 and has held it in 17 quarters since. The position peaked at $6.01M in Q4 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Paul Tudor Jones held 522,663 shares of Ocular Therapeutix worth $5.13M as of Q2 2026.
  • Paul Tudor Jones sold 91,715 Ocular Therapeutix shares in Q2 2026, an estimated $831K.
  • Ocular Therapeutix made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1262 holding.
  • Paul Tudor Jones first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 17 quarters since.
  • Paul Tudor Jones's Ocular Therapeutix position peaked at $6.01M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.